Table 1.
Selective studies of combining HAIC with systemic chemotherapy for colorectal cancer.
| Authors | Year | Setting | Treatment | Line | Inclusion population |
Patient no. (treata) |
Median OS (months) | RR | Note |
|---|---|---|---|---|---|---|---|---|---|
| Yamaguchi et al. [26] |
2011 | Pro, phase I/II |
HAIC → 5-FU IV → CPT-11 + LV Oral tegafur/uracil |
First line | Unresectable hepatic mets | Phase 1: 12 (12) Phase 2: 22 (22) |
Not reach | 86.4% | RCR: 63.6% |
|
| |||||||||
| Mancini et al. [27] |
2003 | Pro, Ran | Arm1: HAIC → continuous cisplatin IV → 5-FU Arm2: HAIC → bolus cisplatin IV → 5-FU |
First line | Unresectable hepatic mets | 58 (58) 65 (65) |
18 | 52% | |
|
| |||||||||
| Goéré et al. [28] | 2010 | Ret | HAIC → oxaliplatin IV → 5-FU + LV |
First line: 18 Second line: 69 |
Unresectable hepatic mets | 87 (87) |
NM | 55% | 5-year survival: 56% |
|
| |||||||||
| Gallagher et al. [29] |
2007 | Ret | HAIC → FUDR + Dexa IV → CPT-11 |
Failed oxaliplatin | Unresectable hepatic mets | 39 (39) | 18 | 44% | |
|
| |||||||||
| Pilati et al. [30] |
2009 | Ret | Arm1: HAIC → FUDR + LV Arm2: HAIC → FUDR + LV IV → 5-FU + LV |
NM | Unresectable hepatic mets | 72 (72) 81 (81) |
18 19.1 |
52.7% 50.6% |
|
Selected studies that enroll patients with colorectal cancer to receive systemic chemotherapy in combination with HAIC are listed here. Studies designed for patients with colorectal cancer-related liver-confined metastatic disease were listed in Table 2.
*With statistical significance.
aActual patients' number who received treatment.
Abbreviations—OS: overall survival, RR: response rate, Pro: prospective, Ran: randomized, Ret: retrospective, NM: not mentioned, HAIC: hepatic artery infusion chemotherapy, IV: intravenous, FUDR: floxuridine, LV: leucovorin, Dexa: dexamethasone, CPT-11: irinotecan, Mets: metastasis, and RCR: resectability conversion rate.